Skip to main content
TipRanks
Go Ultimate75% OFF

Relmada Therapeutics (RLMD) AI Stock Analysis

446 Followers
RLMD

Relmada Therapeutics

(NASDAQ:RLMD)

Select Model
Rating:58Neutral
Price Target:$4.50â–²(6.89% Upside)
Action:reiterated
Date:11/13/26

The score is constrained primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn), partially offset by a strong debt-free balance sheet and improved equity position. Earnings call content is a meaningful positive due to defined IND/Phase 3 timelines, favorable early clinical signals, and an operating runway projected through 2029. Technicals add modest support via improving short-term momentum, while valuation remains unattractive/less informative due to negative earnings and no dividend.

Positive Factors
Long Operating RunwayA cash position expected to fund operations through 2029 gives Relmada time to advance its registrational studies without near-term financing pressure. This supports execution of major development milestones and provides greater flexibility while the company remains pre-commercial.
Negative Factors
Pre-Revenue LossesRelmada has not yet demonstrated commercial revenue or profitability, leaving its economic model dependent on successful clinical development and eventual approval. Continued losses increase the time and execution required before the company can become self-sustaining.

Relmada Therapeutics (RLMD) vs. SPDR S&P 500 ETF (SPY)

-50%-25%0%25%50%75%100%RLMD-1.41%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$449.08M
Dividend Yield
―
Average Volume (3M)
1.36M
Price to Earnings (P/E)
-5.7
Beta (1Y)
1.30
Revenue Growth
―
EPS Growth
58.31%
Country
US
Employees
17
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Relmada Therapeutics Business Overview & Revenue Model

Company Description

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clin...

Relmada Therapeutics Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:1.20%|Next Earnings Date:Mar 23, 2027
Earnings Call SentimentPositive

The call was broadly positive, driven by continued NDV-01 manufacturing progress, expected year-end 2026 IND filings, strong reported complete response rates, durable 18-month responses, a favorable safety profile, and cash resources expected to fund operations through 2029. The main negatives were two progressions to muscle-invasive disease, the limited evaluable 18-month cohort, ongoing manufacturing and stability work, the absence of a completed analysis for the second-line target population, and higher research and development spending and operating cash use.

Positive Updates

NDV-01 Manufacturing Progress and IND Timeline
Relmada made significant progress in the NDV-01 manufacturing process and remains on track to submit the IND by year-end 2026. The company said IND clearance would allow it to begin the registrational Phase 3 program.

Negative Updates

Two Patients Progressed to Muscle-Invasive Disease
Two patients progressed to muscle-invasive disease at month 15: one BCG-naive T1 patient and one BCG-naive CIS with T1 patient. Both had been responders through 12 months, and management said there were no early warning signs. The patients did not fully comply with maintenance dosing between months 12 and 15, which management said could have been one factor, although it did not know whether it contributed.

Company Guidance

Relmada expects to submit the IND for NDV-01 by year-end 2026, initiate the Phase 3 SPECTRUM program upon IND clearance, and file the sepranolone IND by year-end 2026, with the Phase 2 proof-of-concept study expected to begin upon IND clearance; if the IND gets cleared in a reasonable amount of time, that can be 30, 45 days, including the holidays in between, the company should be able to enroll the first patient within the first quarter of next year, and its current cash position is expected to fund company operations through 2029, including completion of the registrational Phase 3 NDV-01 SPECTRUM studies.

Relmada Therapeutics Financial Statement Overview

Summary

Pre-revenue profile with substantial ongoing losses (TTM net income about -$65.7M) and meaningful cash burn (TTM operating/free cash flow about -$51.9M) weigh heavily. Offsetting strengths include a debt-free balance sheet and a materially stronger equity base in TTM, improving financial flexibility despite negative returns.

Income Statement

12Very Negative

Balance Sheet

54Neutral

Cash Flow

23Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit000000
EBITDA-64.93M-57.39M-79.98M4.91M-157.04M-125.75M
Net Income-65.70M-57.39M-79.98M-98.79M-157.04M-125.75M
Balance Sheet
Total Assets205.30M94.00M45.82M97.55M152.91M223.33M
Cash, Cash Equivalents and Short-Term Investments202.12M93.01M44.91M96.32M148.32M211.91M
Total Debt000000
Total Liabilities11.56M7.49M10.30M12.19M12.47M15.06M
Stockholders Equity193.74M86.51M35.52M85.36M140.44M208.26M
Cash Flow
Free Cash Flow-51.86M-45.79M-51.76M-51.66M-103.80M-91.87M
Operating Cash Flow-51.86M-45.79M-51.76M-51.66M-103.80M-91.87M
Investing Cash Flow-187.62M-48.14M51.56M50.45M19.73M-54.12M
Financing Cash Flow243.81M93.56M-40.34K-98.46K45.02M187.94M

Relmada Therapeutics Technical Analysis

Technical Analysis SentimentPositive
Last Price4.21

Price Trends

50DMA3.77Positive
100DMA4.55Negative
200DMA5.37Negative

Market Momentum

MACD0.17Negative
RSI59.30Neutral
STOCH64.79Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RLMD, the sentiment is Positive. The current price of 4.21 is above the 20-day moving average (MA) of 3.71, above the 50-day MA of 3.77, and below the 200-day MA of 5.37, indicating a neutral trend. The MACD of 0.17 indicates Negative momentum. The RSI at 59.30 is Neutral, neither overbought nor oversold. The STOCH value of 64.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RLMD.

Relmada Therapeutics Risk Analysis

Relmada Therapeutics disclosed 82 risk factors in its most recent earnings report. Relmada Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Relmada Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RLMD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
RLMDRLMD58Neutral$449.19M-5.69-37.25%――58.31%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HOWLHOWL50Neutral$47.64M-1.71-187.29%――64.23%
SPRBSPRB47Neutral$124.47M-1.24-118.22%―-100.00%58.95%
PRLDPRLD38Underperform$275.32M-4.37-75.35%―220.34%55.73%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%RLMDXBITPRLDSPRBHOWLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RLMD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RLMDRelmada Therapeutics Inc4.210.246.05%
XBITXBiotech Inc.1.96-0.51-20.65%
PRLDPrelude Therapeutics, Inc.3.451.80109.09%
SPRBSpruce Biosciences, Inc.43.31-65.53-60.21%
HOWLWerewolf Therapeutics, Inc.0.980.066.64%

Relmada Therapeutics Corporate Events

Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements

Relmada Therapeutics Reports Third-Quarter Results and Business Update

Positive
Nov 12, 2026

On November 12, 2026, Relmada Therapeutics reported third-quarter financial results and a business update. Initial 18-month results from its ongoing Phase 2 NDV-01 study showed that 86% of evaluable patients who reached 18 months remained in complete...

Business Operations and StrategyExecutive/Board Changes

Relmada Therapeutics Announces Urology Chief Medical Officer Exit

Negative
Sep 8, 2026

Relmada Therapeutics, Inc. reported that the employment of Dr. Raj S. Pruthi as Chief Medical Officer – Urology ended on September 3, 2026. The departure marks a change in the company’s senior medical leadership in urology, which may influence its cl...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026